Loading...
XASX
OCC
Market cap131mUSD
Oct 09, Last price  
0.69AUD
1D
-0.72%
1Q
-18.34%
Jan 2017
81.58%
IPO
86.49%
Name

Orthocell Ltd

Chart & performance

D1W1MN
XASX:OCC chart
P/E
—
P/S
16.47
EPS
—
Div yield, %
—
Shrs. gr., 5y
7.10%
Rev. gr., 5y
62.14%
Revenues
11m
+51.07%
524,281691,405790,430666,499529,818619,179945,657719,5231,017,9621,531,7184,243,0695,315,3757,550,68111,407,156
Net income
-14m
L+62.43%
-1,323,330-2,182,185-3,742,715-3,784,864-4,177,416-5,757,114-5,852,214-6,151,029-9,037,025-9,106,585-6,248,181-7,180,959-8,566,640-13,914,694
CFO
-13m
L+53.37%
-290,572-1,753,026-2,767,613-3,321,118-3,555,380-4,644,252-4,180,466-5,256,871-4,633,330-6,261,45614,592,580-6,505,126-8,682,928-13,317,110

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.

Key people

John Van Der Wielen
Independent Non-Executive Chairman of the Board · since 2023
Jim Piper
Chief Financial Officer · since 2025
Nicole Telford
Chief Financial Officer
Ming Hao Zheng
Chief Scientific Officer
Paul Anderson
Managing Director, Executive Director · since 2006
Peter Webse
Company Secretary · since 2023
Ravi Thadhani
Lead Independent Director · since 2025
Michael Mcnulty
Non-Executive Director · since 2025
Fiona Wood
Independent Non-Executive Director · since 2023
IPO date
Aug 12, 2014
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT